Abstract
Catechol-O-methyltransferase inhibitor addition to levodopa/carbidopa formulations improves motor symptoms and reduces levodopa fluctuations in patients with Parkinson’s disease. Objectives were to investigate the effects of entacapone and tolcapone on plasma behaviour of levodopa, its metabolite 3-O-methyldopa and on motor impairment. 22 patients orally received levodopa/carbidopa first, then levodopa/carbidopa/entacapone and finally levodopa/carbidopa plus tolcapone within a 4.5 h interval twice. Maximum concentration, time to maximum level and bioavailability of levodopa did not differ between all conditions each with 200 mg levodopa application as a whole. Catechol-O-methyltransferase inhibition caused less fluctuations and higher baseline levels of levodopa after the first intake and less 3-O-methyldopa appearance. The maximum levodopa concentrations were higher after the second levodopa intake, particularly with catechol-O-methyltransferase inhibition. The motor response to levodopa was better with catechol-O-methyltransferase inhibition than without, tolcapone was superior to entacapone. More continuous levodopa brain delivery and lower 3-O-methyldopa bioavailability caused a better motor response during catechol-O-methyltransferase inhibition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Block G, Liss C, Reines S, Irr J, Nibbelink D (1997) Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 37:23–27
Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ (2002) 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. Synapse 43:201–207
Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 41:261–309
Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC, Kjaer MO, Kristensen TN, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Buch D (1996) Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93:14–20
Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM (2001) Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin Neuropharmacol 24:295–299
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508
Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A (2009) Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. Mov Disord 24:541–550
Hauser RA, Ellenbogen AL, Metman LV, Hsu A, O’Connell MJ, Modi NB, Yao HM, Kell SH, Gupta SK (2011) Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s disease. Mov Disord 26:2246–2252
Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamaki M, Ellmen J (2012) The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations. Eur J Clin Pharmacol 68:281–289
Kuoppamaki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hanninen J, Loyttyniemi E, Kailajarvi M, Ruokoniemi P, Ellmen J (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65:443–455
Müller T (2010) The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson’s disease. Clin Med Insights: Ther 2:155–168
Müller T (2013) Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Clin Neuropharmacol 36:84–91
Müller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, Goetze O (2006a) Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 29:61–67
Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006b) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. J Neural Transm 113:1441–1448
Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D (2006c) Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 21:332–336
Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 21:584–588
Nyholm D, Johansson A, Lennernas H, Askmark H (2012) Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol 19:820–826
Russ H, Müller T, Woitalla D, Rahbar A, Hahn J, Kuhn W (1999) Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 360:719–720
Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P (2005) Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 20:306–314
Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18–27
Tolcapone Switch Study Investigators (2007) Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord 22:14–19
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653
Wade LA, Katzman R (1975) 3-O-methyldopa uptake and inhibition of l-dopa at the blood–brain barrier. Life Sci 17:131–136
Acknowledgments
We thank the patients, who participated in this study. We thank Tanja Steiner, Christine Stamm, Ulrike Beckmann, Marion Frickmann, Christa Kraushaar-Szesni for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muhlack, S., Herrmann, L., Salmen, S. et al. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition. J Neural Transm 121, 1357–1366 (2014). https://doi.org/10.1007/s00702-014-1213-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-014-1213-3